Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352184 | PMC |
| http://dx.doi.org/10.3945/an.114.007831 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SPOON: an observational, cross-sectional study of perceptions and expectations of adults with generalised myasthenia gravis in France.
BMJ Open
December 2024
Centre de Référence des Maladies Neuromusculaires AOC, Service de Neurologie et Maladies Neuromusculaires, FILNEMUS, EURO-NMD, Centre Hospitalier Universitaire de Bordeaux Groupe hospitalier Pellegrin, Bordeaux, Aquitaine, France.
Article Synopsis
- The study aimed to understand how patients with myasthenia gravis (MG) perceive their condition and identify potential improvements in treatment.
- Patients over 12 months with the disease participated in an online survey, resulting in 246 completed responses.
- Key findings highlighted participants' desires for better physical activity, reduced fatigue, and suggested treatment improvements, including fewer side effects and simpler medication regimens.
The authors reply.
Kidney Int
October 2024
Centro de Tecnologia da Informação (CTI) Renato Archer, Campinas, São Paulo, Brazil.
Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors.
Crit Rev Oncol Hematol
November 2024
Department of Medicine, Weill Cornell Medicine, Englander Institute for Precision Medicine, New York Presbyterian Hospital, New York, NY 10021, USA.
Circulating tumor cells (CTCs) enumeration and molecular profiling hold promise in revolutionizing the management of solid tumors. Their understanding has evolved significantly over the past two decades, encompassing pivotal biological discoveries and clinical studies across various malignancies. While for some tumor types, such as breast, prostate, and colorectal cancer, CTCs are ready to enter clinical practice, for others, additional research is required.
View Article and Find Full Text PDFStandardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer.
Crit Rev Oncol Hematol
September 2024
Division of Pathology, European Institute of Oncology IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. Electronic address:
Mutations in the estrogen receptor alpha gene (ESR1) can lead to resistance to endocrine therapy (ET) in hormone receptor-positive (HR+)/ HER2- metastatic breast cancer (MBC). ESR1 mutations can be detected in up to 40 % of patients pretreated with ET in circulating tumor DNA (ctDNA). Data from prospective randomized trials highlight those patients with HR+/HER2- MBC with detectable ESR1 mutations experience better outcomes when receiving novel selective estrogen receptor degraders (SERDs).
View Article and Find Full Text PDFLetters in Reply on: "Breastfeeding Ability After Breast Reductions: What does the Literature Tell us in 2023?".
Aesthetic Plast Surg
April 2024
Department of Plastic Surgery, University of South Florida, 2 Tampa General Circle, 7th Floor, Tampa, FL, 33606, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!